Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
/ 60 items
#XY News-Driven Stocks↓
AstraZeneca Shares Rebound After Bristol Myers Deal Rumors Quashed
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
P&G Buys Thorne for $3.8 Billion to Boost Health and Wellness Business
CEO announces the deal on CNBC.
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Pharma Merger
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
Private-Equity Firm KKR Near Agreement to Take Medical-Device Maker Integer Holdings Private
KKR nears deal to take Integer Holdings private at $127/share. Announcement possible next week; values the medical-device CDMO at ~$4.3B.